Cantley Lab

You are here


Boxer MB, Jiang J-K, Heiden MGVander, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HWon et al..  2010.  Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.. J Med Chem. 53(3):1048-55.
Jiang J-K, Boxer MB, Heiden MGVander, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HWon et al..  2010.  Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.. Bioorg Med Chem Lett. 20(11):3387-93.
Heiden MGVander, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM et al..  2010.  Evidence for an alternative glycolytic pathway in rapidly proliferating cells.. Science. 329(5998):1492-9.
Choo AY, Kim SGyun, Heiden MGVander, Mahoney SJ, Vu H, Yoon S-O, Cantley LC, Blenis J.  2010.  Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply.. Mol Cell. 38(4):487-99.
Heiden MGVander, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, Xian J, Cantley LC.  2010.  Identification of small molecule inhibitors of pyruvate kinase M2.. Biochem Pharmacol. 79(8):1118-24.
Yuan TL, Cantley LC.  2010.  Introduction.. Curr Top Microbiol Immunol. 346:1-7.
Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, Luo F, Cantley LC, Wyllie AH, Adams DJ et al..  2010.  PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice.. Proc Natl Acad Sci U S A. 107(34):15145-50.
Taniguchi CM, Winnay J, Kondo T, Bronson RT, Guimaraes AR, Alemán JO, Luo J, Stephanopoulos G, Weissleder R, Cantley LC et al..  2010.  The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.. Cancer Res. 70(13):5305-15.
Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS et al..  2010.  Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer.. Br J Cancer. 103(7):1025-33.
Locasale JW, Heiden MGVander, Cantley LC.  2010.  Rewiring of glycolysis in cancer cell metabolism.. Cell Cycle. 9(21):4253.
Myers AP, Cantley LC.  2010.  Targeting a common collaborator in cancer development.. Sci Transl Med. 2(48):48ps45.
Wong K-K, Engelman JA, Cantley LC.  2010.  Targeting the PI3K signaling pathway in cancer.. Curr Opin Genet Dev. 20(1):87-90.
Smith A, Blois J, Yuan H, Aikawa E, Ellson C, Figueiredo J-L, Weissleder R, Kohler R, Yaffe MB, Cantley LC et al..  2009.  The antiproliferative cytostatic effects of a self-activating viridin prodrug.. Mol Cancer Ther. 8(6):1666-75.
Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C et al..  2009.  Bidirectional transport of amino acids regulates mTOR and autophagy.. Cell. 136(3):521-34.
Schweitzer MH, Zheng W, Organ CL, Avci R, Suo Z, Freimark LM, Lebleu VS, Duncan MB, Heiden MGVander, Neveu JM et al..  2009.  Biomolecular characterization and protein sequences of the Campanian hadrosaur B. canadensis.. Science. 324(5927):626-31.
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HGyung, Jin S, Keenan MC et al..  2009.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.. Nature. 462(7274):739-44.
Locasale JW, Cantley LC, Heiden MGVander.  2009.  Cancer's insatiable appetite.. Nat Biotechnol. 27(10):916-7.
Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, Barretina J, Lin WM, Rameh L, Salmena L et al..  2009.  Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.. Cancer Cell. 16(2):115-25.
Myers AP, Meyerhardt JA, Cantley LC.  2009.  Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy? Clin Cancer Res. 15(22):6748-50.
Cantley LC.  2009.  Lewis C. Cantley.. Curr Biol. 19(14):R540-1.
Zheng B, Jeong JH, Asara JM, Yuan Y-Y, Granter SR, Chin L, Cantley LC.  2009.  Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.. Mol Cell. 33(2):237-47.
Mouta-Bellum C, Kirov A, Miceli-Libby L, Mancini ML, Petrova TV, Liaw L, Prudovsky I, Thorpe PE, Miura N, Cantley LC et al..  2009.  Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha.. Dev Dyn. 238(10):2670-9.
Hill JW, Xu Y, Preitner F, Fukuda M, Cho Y-R, Luo J, Balthasar N, Coppari R, Cantley LC, Kahn BB et al..  2009.  Phosphatidyl inositol 3-kinase signaling in hypothalamic proopiomelanocortin neurons contributes to the regulation of glucose homeostasis.. Endocrinology. 150(11):4874-82.
Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, Hahn WC, Cantley LC.  2009.  Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.. Mol Cell. 34(4):461-72.
Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P, Cantley LC et al..  2009.  PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.. J Clin Oncol. 27(9):1477-84.